← TrialMatch
HomeTrials

Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Se

A clinical study to explore the safety, efficacy and cell metabolic kinetics of universal CD19/20 car-t cell injection in moderate to severe refractory systemic lupus erythematosus. This study is a single arm, open, exploratory dose increasing clinical study, which aims to evaluate the safety, efficacy and cell metabol

Condition(s)Systemic Lupus Erythematosus (SLE)
StatusRecruiting
PhasePhase 1
Study typeInterventional
SummaryA clinical study to explore the safety, efficacy and cell metabolic kinetics of universal CD19/20 car-t cell injection in moderate to severe refractory systemic lupus erythematosus. This study is a single arm, open, exploratory dose increasing clinical study, which aims to evaluate the safety, efficacy and cell metabolic dynamics of ct1192 cells in patients with SLE.
Who can participateInclusion Criteria: 1. Meet the EULAR/ACR 2019 SLE classification criteria, with a medical history of ≥ 6 months; 2. Voluntarily sign the Informed Consent Form (ICF); When signing the ICF, the age range is between 18 and 60 years old (including 18 and 60 years old), with no gender restrictions; 3. No systemic active infections (such as infectious pneumonia or tuberculosis) within the first 2 weeks of screening; 4. Women with fertility (defined as all physiologically capable women) must agree to use effective contraceptive methods from at least 28 days prior to the start of vaginal discharge until 1 year after CT1192 infusion. Egg donation is strictly prohibited within 1 year after receiving the study treatment infusion during the study period. Male partners with fertility must agree to use
Ages18 Years to 60 Years
SexAll
Lead sponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
LocationsWuhan, Hubei, China
Start date2025-07-11
NCT IDNCT07031713
Official listinghttps://clinicaltrials.gov/study/NCT07031713

🔍 Search all trials →